Immunization with the vaccine BCR-ABL/GM-CSF/IL-12 and the TLR-9 agonist dSLIM combined with 6-MP induces an innate and adaptive immune response and leads to a very high survival rate in an ALL mouse model (Köchling et al., 2012). This evidence concerns the gene TLR9 and acute lymphoblastic leukemia.